Tuesday, October 4, 2022

The History of WEF's Origins

Posted by at No comments:
Labels:

Eugene Yu, CEO OF Konnech Inc. has been arrested by the LA County District Attorney

An arrest suggests it's a little more than just conspiracy.  His company, Konnech, provides the electronic software for elections, and I presume that means to tally votes as well.  Given the hot political climate with regard to voting systems, you'd thikn they would re-worded the sales message on their landing page, 

first-client partnership with the City of Detroit to the 32 clients we currently work with in North America, our Founder and President, Eugene Yu, has implemented a client-centered approach. We listen to what you need in a system and will configure and customize our products so that you receive the exact solution you need.

Posted by at No comments:
Labels: , ,

Melatonin has shown significant benefits in reducing cardiac pathology, and preventing the death of cardiac muscle in response to ischemia-reperfusion . . .

Melatonin has shown significant benefits in reducing cardiac pathology, and preventing the death of cardiac muscle in response to ischemia-reperfusion in rodent species.  Moreover, melatonin may also prevent the hypertrophy of the heart muscle  under some circumstances, which in turn would lessen the development of heart failure.

Posted by at No comments:
Labels: , ,

MELATONIN: For neuro-protection, not just sleep inducement, a lot melatonin is required: 50-100mg.

Below are the sections of each abstract that I thought were interesting and helpful. 

ABSTRACT #1

Melatonin is selectively taken up by mitochondrial membranes, a function not shared by other anti-oxidants, and thus has emerged as a major potential therapeutic tool for treating neurodegenerative disorders. Multiple in vitro and in vivo experiments have shown the protective role of melatonin for preventing oxidative stress-induced mitochondrial dysfunction seen in experimental models of PD, AD, and HD.  https://pubmed.ncbi.nlm.nih.gov/26087000/

For neuro-protection, not just sleep inducement, a lot melatonin is required: 50-100mg.    

ABSTRACT #2

Both in vitro and in vivo, melatonin was effective to prevent oxidative stress/nitrosative stress-induced mitochondrial dysfunction seen in experimental models of AD, PD and HD. These effects are seen at doses 2-3 orders of magnitude higher than those required to affect sleep and circadian rhythms, both conspicuous targets of melatonin action. Melatonin is selectively taken up by mitochondria, a function not shared by other antioxidants. A limited number of clinical studies indicate that melatonin can improve sleep and circadian rhythm disruption in PD and AD patients. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50-100mg/day are needed to assess its therapeutic validity in neurodegenerative disorders.  https://pubmed.ncbi.nlm.nih.gov/22391273/

ABSTRACT #3

Melatonin is a tryptophan-derived ancestral molecule evolved in bacteria.

Throughout the aging process melatonin levels tend to reduce and as a manifestation of this, many symptoms in organisms' homeostasis, such as deterioration in adjustment of cellular clocks, are commonly seen. In addition, due to deterioration in mitochondrial integrity and functions, immunity decreases, and lower levels of melatonin renders older individuals to be more susceptible to impaired redox modulation and age-related diseases.  https://pubmed.ncbi.nlm.nih.gov/35895186/

Posted by at No comments:
Labels: , , , ,

Job Offerings Falling Precipitously

Posted by at No comments:
Labels: ,
Subscribe to: Posts (Atom)